Welcome to our dedicated page for Orthofix Medical SEC filings (Ticker: OFIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Orthofix Medical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Orthofix Medical's regulatory disclosures and financial reporting.
Orthofix Medical Inc. director Jason Hannon reported receiving an award of 14,965 deferred stock units of common stock on June 10, 2026. These units vest in full on the first anniversary of the grant date, as long as he continues serving the company.
Each deferred stock unit represents a contingent right to receive one share of Orthofix common stock, which will be delivered within 45 days after his service with the company ends. Following this grant, Hannon directly holds 87,662 deferred stock units and shares, including 63,631 previously reported deferred stock units and 2,103 shares acquired through Orthofix's Stock Purchase Plan.
Orthofix Medical Inc. director Michael Finegan reported receiving an award of 20,721 deferred stock units of common stock. These units vest in full on the first anniversary of the grant date, contingent on his continued service. Each deferred stock unit represents the right to receive one Orthofix common share, which will be delivered within 45 days after his service with the company ends. Following this award and previously reported positions, Finegan now holds a total of 81,617 Orthofix shares and deferred stock units, including 55,805 earlier deferred units and 3,505 shares acquired under Orthofix's Stock Purchase Plan.
Orthofix Medical Inc. director Vickie L. Capps received a grant of 14,965 deferred stock units of common stock on the grant date. The award vests in full on the first anniversary of the grant, contingent on continued board service, and each unit represents the right to one share.
After this grant, Capps directly holds 43,300 shares and deferred stock units in total, including 21,934 previously reported deferred stock units and 750 shares acquired under Orthofix's Stock Purchase Plan. Vested deferred stock units will convert into common stock within 45 days after her service with Orthofix ends.
HENNEMAN JOHN B III reported acquisition or exercise transactions in this Form 4 filing.
Orthofix Medical Inc. director John B. Henneman III received an equity award of 14,965 deferred stock units on common stock. The units were granted at no cash cost and vest in full on the first anniversary of the grant date, contingent on continued board service.
Each deferred stock unit represents a right to receive one share of Orthofix common stock, which will be delivered within 45 days after his service with the company ends. Following this award, Henneman holds 105,774 shares and units directly, including 48,347 deferred stock units that were previously reported.
BURRIS WAYNE reported acquisition or exercise transactions in this Form 4 filing.
Orthofix Medical Inc. director Wayne Burris received a grant of 14,965 deferred stock units of common stock at no cost. These units vest in full on the first anniversary of the grant date, contingent on his continued service with the company through that date.
Each deferred stock unit represents a contingent right to receive one share of Orthofix common stock, settling within 45 days after his service with the company ends. Including 44,156 previously reported deferred stock units, his direct holdings now total 65,504 shares represented by deferred stock units.
Maniar Shweta reported acquisition or exercise transactions in this Form 4 filing.
Orthofix Medical Inc. director Shweta Maniar received an award of 14,965 deferred stock units of common stock at no purchase price as equity compensation. The units vest in full on the first anniversary of the grant date, conditioned on continued service. Each unit represents a contingent right to receive one share of common stock, which will be delivered within 45 days after her service with the company ends. Following this grant, she holds a total of 69,038 deferred stock units, including 48,347 units that were previously reported.
Orthofix Medical Inc. director Michael E. Paolucci received an equity compensation grant of 14,965 deferred stock units of common stock at no cost. These units vest in full on the first anniversary of the grant date, subject to his continued service. Each vested unit will convert into one share of common stock within 45 days after his service with the company ends. Following this award, he directly holds 102,727 units and shares, including 73,541 previously reported deferred stock units and 814 shares acquired under Orthofix's Stock Purchase Plan.
Orthofix Medical Inc. reported results of its 2026 Annual Meeting of Shareholders and approval of an amendment to its employee stock purchase plan. Shareholders approved Amendment No. 5 to the Second Amended and Restated Stock Purchase Plan, increasing the number of common shares available for issuance under the plan by 1,250,000 shares, with no other changes to the plan’s terms.
The company also confirmed that a quorum was present, with 34,776,676 common shares represented out of 40,385,869 shares eligible to vote as of the April 13, 2026 record date. Shareholders voted on the election of directors, with each listed nominee receiving substantially more votes “for” than “against,” and certain votes counted as broker non-votes for specified items.
Orthofix Medical Inc. reported an insider transaction involving funds managed by Juniper Investment Company, LLC. A Form 4 shows that Juniper Targeted Opportunity Fund, L.P., for which Juniper Investment Company acts as investment manager, completed an open-market sale of 242,000 shares of Orthofix common stock at a weighted average price of $10.6992 per share, with individual trade prices ranging from $10.2450 to $10.9500. After this sale, Juniper Targeted Opportunity Fund, L.P. held 3,461,216 shares indirectly. Related funds advised by Juniper Investment Company also held 45,426 shares through Juniper Multi-Strategy Fund, L.P. and 935,901 shares through Juniper Targeted Opportunities, L.P. Juniper Investment Company, and managing members John A. Bartholdson and Alexis P. Michas, state they may be deemed to beneficially own these holdings but disclaim beneficial ownership beyond their pecuniary interest.
Orthofix Medical Inc. received a Form 3 from Juniper Investment Company, LLC and related persons, reporting their status as ten percent owners of Orthofix common stock. The filing lists indirect holdings of Orthofix shares through Juniper Targeted Opportunity Fund, Juniper Targeted Opportunities and Juniper Multi-Strategy funds.
Juniper Investment Company, as investment manager to these funds, may be deemed to beneficially own the funds’ Orthofix shares, while disclosing that it, and managing members John A. Bartholdson and Alexis P. Michas, disclaim beneficial ownership except to the extent of their pecuniary interests.